Mechanisms of Disease: the link between RANKL and arthritic bone disease (Q36577375)

15 August 2017

1 reference

title

Mechanisms of Disease: the link between RANKL and arthritic bone disease (English)

1 reference

15 August 2017

5

Josef S Smolen

1 reference

15 August 2017

1

Georg Schett

1 reference

15 August 2017

Silvia Hayer

2

1 reference

15 August 2017

Jochen Zwerina

series ordinal

3

1 reference

15 August 2017

Kurt Redlich

series ordinal

4

1 reference

15 August 2017

publication date

1 November 2005

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

published in

1 reference

15 August 2017

volume

1

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

47-54

1 reference

The complexities of skeletal biology

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Bone resorption by osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Analysis of the kinetics of osteoclastogenesis in arthritic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Soluble RANKL and risk of nontraumatic fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

OSTEOPOROSIS IN RHEUMATOID ARTHRITIS—THE CLINICAL VIEWPOINT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

Risk of vertebral fracture in women with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

Generalised bone loss in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

Rheumatoid arthritis, corticosteroid therapy and hip fracture

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

The links between joint damage and disability in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

Osteoclasts are essential for TNF-alpha-mediated joint destruction

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

Expression of osteoclast differentiation factor in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthr

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

Bisphosphonates: environmental protection for the joint?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

The effect of a single dose of osteoprotegerin in postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0036

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0036

1 reference

15 August 2017

1 reference